AVXL Stock Overview
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Anavex Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.52 |
| 52 Week High | US$15.24 |
| 52 Week Low | US$7.13 |
| Beta | 0.74 |
| 1 Month Change | 28.45% |
| 3 Month Change | -14.19% |
| 1 Year Change | -13.56% |
| 3 Year Change | 267.83% |
| 5 Year Change | 306.18% |
| Change since IPO | 15,679.68% |
Recent News & Updates
Recent updates
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16
We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Apr 16Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Jan 01Shareholder Returns
| AVXL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.1% | 0.7% | 2.3% |
| 1Y | -13.6% | 7.1% | -9.7% |
Return vs Industry: AVXL underperformed the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: AVXL underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| AVXL volatility | |
|---|---|
| AVXL Average Weekly Movement | 17.2% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AVXL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: AVXL's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 38 | Chris Missling | https://www.anavex.com |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases.
Anavex Life Sciences Corp. Fundamentals Summary
| AVXL fundamental statistics | |
|---|---|
| Market Cap | US$820.16m |
| Earnings (TTM) | -US$47.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-17.1x
P/E RatioIs AVXL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVXL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$47.98m |
| Earnings | -US$47.98m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AVXL perform over the long term?
See historical performance and comparison